PROPRANOLOL hydrochloride (Inderal), a new beta adrenergic receptor blocking agent, apparently possessing a potency ten to 20 times that of its predecessor, pronetalol,1yet lacking its tumor producing qualities in mice,2recently has received clinical trial in the treatment of angina pectoris. Strivastava and associates3using propranolol, 20 mg three times daily in a double-blind study of 20 patients exhibiting angina pectoris, found no statistically significant difference in frequency of angina pectoris or nitroglycerin consumption. However, Keelan4in a similar study of 19 patients but employing larger doses of propranolol, 30 mg three times daily, observed significant reduction in frequency of angina pectoris and in number of nitroglycerin tablets used. Gillam and Prichard,5utilizing maximum tolerated doses of propranolol, 30 mg to a ceiling of 100 mg four times daily, recorded significant improvement in all 14 patients studied. The present paper reports the results of